Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $49.9M
- Enterprise value
- $49.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $3.15
- 52-wk low
- $0.78
- Beta
- —
- Shares out
- 43.0M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies compared to traditional CAR-T therapies. Leveraging cutting-edge cellular engineering technologies, we aim to overcome the limitations of current CAR-T therapies, such as high toxicity and prohibitive costs, so that T-cell therapy treatments can be accessible to a larger patient population. Lead Program Status Our innovative ARTEMIS® T Cell Receptor…
AI summary unavailable — showing raw filing excerpt
Generated from ESLA's filing dated 2026-03-18
Key risks
Item 1A. Risk Factors. You should consider carefully the risks and uncertainties described below, together with all of the other information contained in this Annual Report. If any of the following events occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business or results of operations.…
AI summary unavailable — showing raw filing excerpt
Generated from ESLA's filing dated 2026-03-18
Profitability
Return on equity
126.0%
33.1%Return on assets
-411.2%
12.0%Leverage
Debt / equity
-1.31×
106.3%Debt / assets
426.3%
346.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-2.3M | -8.9% | — |
Q4 2025 2025-12-31 | — | — | $-613.2K | — | — |
Q3 2025 2025-09-30 | — | — | $-4.8M | -42.2% | — |
Q2 2025 2025-06-30 | — | — | $-5.5M | -40.3% | — |
Q1 2025 2025-03-31 | — | — | $-2.1M | -348.2% | — |
Q3 2024 2024-09-30 | — | — | $-3.4M | -80.5% | — |
Q2 2024 2024-06-30 | — | — | $-4.0M | -5098.5% | — |
Q1 2024 2024-03-31 | — | — | $-469.5K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ESLA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$2.6K
Insider selling
$0
Net activity
+$2.6K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ESLA
Institutional value
$813.2K
Total shares held
767.2K
Distinct holders
6
-9 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 382.5K | $405.4K | — | New |
| 2 | WELLS FARGO & COMPANY/MN | 264.4K | $280.3K | — | New |
| 3 | VANGUARD FIDUCIARY TRUST CO | 64.9K | $68.8K | — | New |
| 4 | BlackRock, Inc. | 39.9K | $42.3K | +13.4K (+50.7%) | Added |
| 5 | UBS Group AG | 15.1K | $16.0K | +11.9K (+373.1%) | Added |
| 6 | WOLVERINE ASSET MANAGEMENT LLC | 468 | $496 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ESLA's latest filing finishes processing.